. Author manuscript; available in PMC: 2014 May 1.

Published in final edited form as: J Hepatol. 2013 Jan 16;58(5):949–955. doi: 10.1016/j.jhep.2013.01.003

Table 5.

Comparison of median fecal bile acid values pre and post rifaximin

Median values in μg/100 mg dry stool	Prospective trial
Median values in μg/100 mg dry stool	Pre rifaximin (n=6)	Post-rifaximin (n=6)
Total Bile Acids	581	526
Primary
CA	21.5	39.3*
CDCA	2.6	19.2*
Secondary
LCA	113.9	118.9
DCA	377.6	354.2
Secondary/Primary Ratios
LCA/CDCA	20.1	3.4*
DCA/CA	13.9	2.5
LCA+DCA / CDCA+CA	17.5	2.5*

^†

p<0.05 in this open-label trial of rifaximin in early cirrhotic patients, there was a net decrease in the secondary/primary BA ratio after rifaximin using the Wilcoxon matched-pairs test.

CA: cholic acid, CDCA: chenodeoxycholic acid, LCA: lithocholic acid, DCA: deoxycholic acid